Pharmaceutical industries Ltd. Of Teva, hosted in Israel, they are between the 35 generic farmacéuticas company farmacéuticas superior and enters the company the greaters in the world. Such indications are based on current plants, estimates and expectations and involve a number risks and of known 50mg ultram and unknown uncertainties that could cause the Company& #039; future results, performance or accomplishments of s to differ significantly from the results, the performance or the accomplishments expressed or implied for such progressive indications. Important factors that they could cause or contribute to such environment and changes in the sanitary politics and the structure of some countries, acceptance and regulating demand for new pharmaceutical products and new therapies, the competitive impact of products and setting of the price, the availability and setting of the price of the ingredients if used in the manufacture of pharmaceutical products, uncertainties regarding the acceptance of the market of the innovative products lanç recently, currently being vendido or during the development process, the impact of the reorganization of the customers, the confidence in a strategy of acquiring company and strategical alliances, the exposition the claims of responsibility ofthe product, the dependence in the patent and the other protections for our innovative products, fluctuations in taxes of the currency, the exchange and interest, results of functioning, and other factors that are argued in the Company& #039; it informs annual of s in the form 20-F and the Company& #039; s other fillings with U. 50mg ultram (nyse: MYL) announced today that the E. 50mg ultram since March 2001, capable one received 14 approvals from WALKS. To the extension all the indications made in this release contain the information that is not historical, these indications are essentially progressive indications regarding our financial results and anticipated estimates, prospects of the business and products in the research and under the 50mg ultram development going, that they involve substantial risks and uncertainties. The indication of the safe port under the shareholders and the shareholders perspective of the E.
U can registar to receive company& automatically; #039; releases 50mg ultram of the press of s through the email in www. Com/ComNewsv2. The expeditions are waited to start immediately. The tablets of hidrocloro of Tramadol are the AB-evaluated generic version of RW Johnson& #039; s Ultram (r) tablets. The progressive indications only speak until a date of the date where they are made, and the company does not undertake no obligation to bring up to date public 50mg ultram or to revise no indication progressive, if in consequence of the new information, the future developments or in another way.
Confidential act of the reform of the litigation of the 1995 security: This release will count the progressive indications, that express the opinion and the expectations of the management. 17, 50mg ultram 2002 pharmaceutical industries of Teva Ltd. (1) Ultram is a registada mark of the important factors that they could cause or contribute to such environment and changes in the sanitary politics and the structure of some countries, acceptance and regulating demand for new pharmaceutical products and new therapies, the competitive impact of products and setting of the price, the availability and setting of the price of the ingredients if it used in the manufacture of pharmaceutical products, uncertainties regarding the acceptance of the market of the innovative products lanç recently, currently being vendido or during the development process, the impact of the reorganization of the customers, confidence in a strategy of acquiring company and strategical alliances, exposition to the claims of responsibility of the product, dependence of Pharmaceutical Ortho-McNeil, Incorporation in the patent and other protections for our innovative products, fluctuations in the currency, taxes of the exchange and interest, results of functioning, and other factors that are argued in the Company& #039; it informs annual of s in the form 20-F and the Company& #039; s other fillings with the U. The company is continuing its aggressive programming of the filling for new submissions of WALKS.